Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that patients with unresectable melanoma treated with AZD6244 experienced skin reactions, including depigmentation and papulopustular rashes, in patterns similar to those caused by EGFR inhibitors.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

This announcement discusses the recent FDA approval of baricitinib for treating severe alopecia areata in adults and reports no new clinical results.

In this study, baricitinib treatment over an average of 18.5 months resulted in a 72% reduction in alopecia severity scores among patients aged 65 or older, with mild adverse effects and no severe complications reported.

Baricitinib helps with early hair regrowth in people with alopecia areata.

In this case report, a young adult male with resistant alopecia areata showed nearly 90% hair regrowth after 3 months of treatment with tofacitinib, alongside biotin supplementation, without any side effects observed.

This study reports that sorafenib-associated facial acneiform eruption, mimicking chloracne, is a rare cutaneous adverse event which improved upon reducing or discontinuing the drug.

This article reviews the use of sorafenib, a multikinase inhibitor, for treating certain carcinomas, noting that cutaneous toxicity during treatment may indicate successful antitumor activity; however, it reports no new clinical results.

This study found that baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata, with similar improvements observed in both clinician-reported and patient-reported measures.

Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.

This clinical study observed that in patients with advanced breast cancer and BRCA1/2 mutations, talazoparib provided significantly better progression-free survival, objective response, clinical benefit, and patient-reported outcomes compared to physician’s choice chemotherapy, despite common side effects like anemia and fatigue.

This study reported a drug-induced pityriasis rubra pilaris-like eruption in a patient treated with sorafenib, suggesting a possible effect of sorafenib on keratinocyte biology.

Baricitinib helps regrow hair in teens with severe alopecia areata.

In this first-in-human study, BLZ-100, an intraoperative fluorescent imaging agent, was administered to 21 patients before skin cancer surgery and was found to be well tolerated without serious adverse effects, suggesting its potential to help distinguish cancerous from non-cancerous tissue based on fluorescence.

This study aimed to evaluate the outcomes of switching between two JAK inhibitors, tofacitinib and baricitinib, in treating alopecia areata, due to the lack of data on their comparative efficacy.

This review details how baricitinib successfully demonstrated significant hair regrowth in clinical trials for severe alopecia areata, now leading to its approval as the first systemic therapy for the condition, while also highlighting the importance of assessing individual risk factors for adverse events.

This case report observed vemurafenib-induced pityriasis amiantacea, a scalp scaling reaction, in a patient with metastatic melanoma, which was managed symptomatically without altering vemurafenib treatment.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This article summarizes dermatologic adverse events in patients treated with afatinib in clinical trials and discusses strategies for managing these side effects, without providing new clinical results.

This case report describes a patient with painful skin lesions during sorafenib treatment whose symptoms improved after receiving photodynamic therapy, suggesting it might help manage similar refractory skin toxicity cases.

This study found that Litfulo improved hair regrowth in patients aged 12 and older with severe alopecia areata but did not meaningfully improve anxiety or depression symptoms compared to placebo.

This phase II trial found that BI 2536 demonstrated limited antitumor activity across five solid tumor types, with no confirmed objective responses observed.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

This article reviews the cutaneous reactions associated with targeted cancer therapies and highlights the importance of dermatologists recognizing these reactions to provide effective care but reports no clinical results.

In this retrospective study, researchers found that baricitinib was effective for treating moderate to severe alopecia areata, with response rates in 24 patients comparable to existing real-world data, and no new safety concerns were identified.

This study found that topical bortezomib increased cell proliferation in hair follicles and sebaceous glands in mice and may activate hair keratin gene expression through GATA-3 transcription factors.

This review summarizes existing studies on sorafenib, noting its promising effects in some cancers, but also highlights its limitations and potential synergy when combined with other anticancer treatments.

In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.